Edition:
United States

Xencor Inc (XNCR.OQ)

XNCR.OQ on NASDAQ Stock Exchange Global Market

29.15USD
4:00pm EDT
Change (% chg)

$-0.73 (-2.44%)
Prev Close
$29.88
Open
$29.87
Day's High
$30.10
Day's Low
$29.05
Volume
67,247
Avg. Vol
108,005
52-wk High
$34.62
52-wk Low
$18.67

Chart for

About

Xencor, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials... (more)

Overall

Beta: 1.48
Market Cap(Mil.): $1,622.56
Shares Outstanding(Mil.): 54.30
Dividend: --
Yield (%): --

Financials

  XNCR.OQ Industry Sector
P/E (TTM): -- 188.22 33.60
EPS (TTM): -1.05 -- --
ROI: -16.01 -0.74 13.19
ROE: -16.42 -2.80 15.00

BRIEF-Xencor Says Public Offering Of 7.30 Mln Common Shares Priced At $31 Per Share

* XENCOR ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

Mar 20 2018

BRIEF-Xencor Files For Potential Mixed Shelf Offering

* XENCOR INC FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED- SEC FILING ‍​ Source text: (http://bit.ly/2G8MdV1) Further company coverage:

Mar 19 2018

BRIEF-Xencor Announces Proposed Public Offering Of Common Stock

* XENCOR, INC. ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

Mar 19 2018

BRIEF-Xencor Reports Q4 Loss Per Share $0.25

* XENCOR REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

Feb 27 2018

BRIEF-Xencor Doses First Patient In Phase 1 Study Of Xmab®18087,An Antibody For Treatment Of Neuroendocrine Tumors And Gastrointestinal Stromal Tumors

* XENCOR DOSES FIRST PATIENT IN PHASE 1 STUDY OF XMAB®18087 BISPECIFIC TUMOR TARGETING ANTIBODY FOR THE TREATMENT OF NEUROENDOCRINE TUMORS AND GASTROINTESTINAL STROMAL TUMORS

Feb 22 2018

BRIEF-Xencor Inc - Expect Initial Data From Phase 2 Trial Of Xmab®5871 In Systemic Lupus Erythematosus

* XENCOR INC - EXPECT INITIAL DATA FROM PHASE 2 TRIAL OF XMAB®5871 IN SYSTEMIC LUPUS ERYTHEMATOSUS

Jan 05 2018

BRIEF-Xencor Receives Milestone Payment From Amgen

* SAYS IT HAS EARNED A $10 MILLION MILESTONE PAYMENT FROM AMGEN

Dec 05 2017

BRIEF-Xencor posts Q3 loss of $0.33 per share

* Xencor reports third quarter 2017 financial results and provides clinical pipeline update

Nov 07 2017

Competitors

  Price Chg
Pfizer Inc. (PFE.N) $36.80 +0.17
Novartis AG (NOVN.S) CHF76.04 -0.04
Roche Holding Ltd. (ROG.S) CHF217.60 +1.95
Roche Holding Ltd. (RO.S) CHF221.40 +1.40
AstraZeneca plc (AZN.L) 5,015.00 +39.00
GlaxoSmithKline plc (GSK.L) 1,445.00 +15.00
AbbVie Inc (ABBV.N) $93.17 +0.57
Bristol-Myers Squibb Co (BMY.N) $50.90 -0.27
Bristol-Myers Squibb Co (BMYMP.PK) $1,306.55 --
Amgen, Inc. (AMGN.OQ) $174.66 +3.10

Earnings vs. Estimates